Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.

CAS  Article  Google Scholar 

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4:38.

Article  Google Scholar 

Imperlini E, Gnecchi M, Rognoni P, Sabido E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 2017;7:15661.

Article  Google Scholar 

Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924–33.

Article  Google Scholar 

Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transpl. 2009;24:3132–7.

CAS  Article  Google Scholar 

Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91:E458–60.

Article  Google Scholar 

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–32.

CAS  Article  Google Scholar 

Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29:674–81.

Article  Google Scholar 

Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N. Engl J Med. 1997;336:1202–7.

CAS  Article  Google Scholar 

Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290–8.

CAS  Article  Google Scholar 

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346–52.

CAS  Article  Google Scholar 

Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–2.

CAS  Article  Google Scholar 

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021;35:916–9.

Article  Google Scholar 

Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90:181–6.

CAS  Article  Google Scholar 

Pasternack A, Ahonen J, Kuhlback B. Renal transplantation in 45 patients with amyloidosis. Transplantation. 1986;42:598–601.

CAS  Article  Google Scholar 

Dorman SA, Gamelli RL, Benziger JR, Trainer TD, Foster RS. Systemic amyloidosis involving two renal transplants. Hum Pathol. 1981;12:735–8.

CAS  Article  Google Scholar 

Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019;95:405–11.

Article  Google Scholar 

Cohen OC, Law S, Lachmann HJ, Sharpley F, Ravichandran S, Mahmood S, et al. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer J. 2020;10:60.

Article  Google Scholar 

Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021;99:707–15.

CAS  Article  Google Scholar 

Law S, Cohen O, Lachmann HJ, Rezk T, Gilbertson JA, Rowczenio D, et al. Renal transplant outcomes in amyloidosis. Nephrol Dial Transpl. 2021;36:355–65.

CAS  Article  Google Scholar 

Sathick IJ, Rosenbaum CA, Gutgarts V, Landau H. Kidney transplantation in AL Amyloidosis: is it time to maximize access? Br J Haematol. 2020;188:e1–4.

Article  Google Scholar 

Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319–28.

Article  Google Scholar 

Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55:499–504.

CAS  Article  Google Scholar 

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

CAS  Article  Google Scholar 

Palladini G, Schonland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1–2.

Article  Google Scholar 

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.

CAS  Article  Google Scholar 

Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027–34.

Article  Google Scholar 

Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl. 2009;9:S1–155.

Google Scholar 

Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, et al. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transpl. 2011;26:2032–6.

Article  Google Scholar 

Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V. Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer J. 2020;10:118.

Article  Google Scholar 

Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016;23:281–6.

Article  Google Scholar 

Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transpl. 2018;18:18–113.

Article  Google Scholar 

Sawinski D, Lim MA, Cohen JC, Locke JE, Weiss B, Hogan JJ, et al. Patient and kidney allograft survival in recipients with end stage renal disease from Amyloidosis. Transplantation. 2018;102:300–9.

Article  Google Scholar